Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Articles published by Beam Therapeutics
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
August 06, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Announces Transition of Chief Financial Officer
July 15, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
June 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
June 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
May 30, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
May 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
May 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
May 07, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
March 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
February 28, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
February 27, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
January 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
December 14, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
November 08, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 08, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
October 31, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
October 25, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
October 19, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
September 07, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
September 05, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in Upcoming September Investor Conferences
August 31, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
August 08, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in Upcoming May Investor Conferences
May 17, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 11, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
May 10, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
March 21, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
March 15, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Tickers
BEAM
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.